




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 487/04, A61K 31/47, A61P 43/00, C07D 401/04 // (C07D 487/04, 235:00, 209:00)	A1	(11) International Publication Number: WO 00/58313 (43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/08196 (22) International Filing Date: 28 March 2000 (28.03.00) (30) Priority Data: 60/126,926 29 March 1999 (29.03.99) US (71) Applicant (for all designated States except US): NEUROGEN CORPORATION [US/US]; 35 Northeast Industrial Road, Branford, CT 06405 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): YUAN, Jun [US/US]; 40 Spruce Hill Drive, Guilford, CT 06437 (US). HUTCHISON, Alan [US/US]; 29 Kimberly Lane, Madison, CT 06437 (US). (74) Agent: SARUSSI, Steven, J.; McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606 (US).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: 4-SUBSTITUTED QUINOLINE DERIVATIVES AS GABA RECEPTOR LIGANDS <div style="text-align: center;">  <p>(I)</p> </div> (57) Abstract <p>Disclosed are compounds of the Formula (I) where R₁, R₂, R₃, R₄, X, Y₁ and Y₂ are defined herein. These compounds bind with high affinity to GABA_A receptors. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating patients suffering from certain central nervous system and peripheral diseases or disorders with these pharmaceutical compositions. This invention also relates to the use of such compounds in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. The compounds of this invention are also useful as probes for the localization of GABA_A receptors.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

4-SUBSTITUTED QUINOLINE DERIVATIVES AS GABA RECEPTOR LIGANDS

Background of the Invention

Field Of The Invention

5 This invention relates to quinoline derivatives, pharmaceutical compositions comprising them, and the use of such compounds in the treatment of certain central nervous system and peripheral diseases or disorders. This invention also relates to the use of such compounds in combination with
10 one or more other CNS agents to potentiate the effects of the other CNS agents. The compounds of this invention are also useful as probes for the localization of cell surface receptors.

Description of the Related Art

 The GABA_A receptor superfamily represents one of the classes of receptors through which the major inhibitory neurotransmitter, γ -aminobutyric acid, or GABA, acts. Widely, although unequally, distributed through the mammalian brain,
20 GABA mediates many of its actions through a complex of proteins called the GABA_A receptor, which causes alteration in chloride conductance and membrane polarization.

 A number of cDNAs for GABA_A receptor subunits have been characterized. To date at least 6 α , 3 β , 3 γ , 1 ϵ , 1 δ and 2 ρ
25 subunits have been identified. It is generally accepted that native GABA_A receptors are typically composed of 2 α , 2 β , and 1 γ subunits (Pritchett & Seeburg *Science* 1989; 245:1389-1392 and Knight et. al., *Recept. Channels* 1998; 6:1-18). Evidence such as message distribution, genome localization and biochemical
30 study results suggest that the major naturally occurring receptor combinations are $\alpha_1\beta_2\gamma_2$, $\alpha_2\beta_3\gamma_2$, $\alpha_3\beta_3\gamma_2$, and $\alpha_5\beta_3\gamma_2$ (Mohler et. al. *Neuroch. Res.* 1995; 20(5): 631 - 636).

 Benzodiazepines exert their pharmacological actions by interacting with the benzodiazepine binding sites associated
35 with the GABA_A receptor. In addition to the benzodiazepine

site, the GABA_A receptor contains sites of interaction for several other classes of drugs. These include a steroid binding site, a picrotoxin site, and the barbiturate site. The benzodiazepine site of the GABA_A receptor is a distinct site on the receptor complex that does not overlap with the site of interaction for GABA or for other classes of drugs that bind to the receptor (see, e.g., Cooper, et al., The Biochemical Basis of Neuropharmacology, 6th ed., 1991, pp. 145-148, Oxford University Press, New York). Early electrophysiological studies indicated that a major action of the benzodiazepines was enhancement of GABAergic inhibition. Compounds that selectively bind to the benzodiazepine site and enhance the ability of GABA to open GABA_A receptor channels are agonists of GABA receptors. Other compounds that interact with the same site but negatively modulate the action of GABA are called inverse agonists. Compounds belonging to a third class bind selectively to the benzodiazepine site and yet have little or no effect on GABA activity, but can block the action of GABA_A receptor agonists or inverse agonists that act at this site. These compounds are referred to as antagonists.

The important allosteric modulatory effects of drugs acting at the benzodiazepine site were recognized early and the distribution of activities at different receptor subtypes has been an area of intense pharmacological discovery. Agonists that act at the benzodiazepine site are known to exhibit anxiolytic, sedative, and hypnotic effects, while compounds that act as inverse agonists at this site elicit anxiogenic, cognition enhancing, and proconvulsant effects. While benzodiazepines have a long history of pharmaceutical use as anxiolytics, these compounds often exhibit a number of unwanted side effects. These may include cognitive impairment, sedation, ataxia, potentiation of ethanol effects, and a tendency for tolerance and drug dependence.

GABA_A selective ligands may also act to potentiate the effects of certain other CNS active compounds. For example,


there is evidence that selective serotonin reuptake inhibitors (SSRIs) may show greater antidepressant activity when used in combination with GABA_A selective ligands than when used alone.

5

SUMMARY OF THE INVENTION

Disclosed are compounds, particularly quinoline derivatives that bind to cell surface receptors. Preferred compounds of the invention bind to neurokinin and/or GABA receptors, in particular these compounds possess affinity for GABA_A receptors. These compounds are therefore considered to be of use in the treatment of a broad array of diseases or disorders in patients which are characterized by modulation of GABA_A receptors.

This invention provides compounds of general Formula I:



Formula I

or pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, wherein in R₁, R₂, R₃, R₄, X, Y₁ and Y₂ are hereinafter defined.

Preferred compounds of this invention are ligands for GABA receptors, GABA_A receptors, and are useful in the treatment of a wide range of diseases or disorders including,

but not limited to depression, anxiety, sleep disorders, cognitive disorders, low alertness, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, Down's syndrome, and
5 benzodiazepine overdoses.

The invention also provides pharmaceutical compositions comprising compounds of Formula I. The invention further comprises a method of treating a patient suffering from certain central nervous system and peripheral diseases or
10 disorders with effective concentration of a compound of the invention. Treatment of humans, domesticated companion animals (pets) or livestock animals suffering such conditions with an effective amount of a compound of the invention is contemplated by the invention.

15 Packaged pharmaceutical compositions including instructions for use of the composition are also included.


In a separate aspect, the invention provides a method of potentiating the actions of other CNS active compounds. This
20 method comprises administering an effective amount of a compound of the invention with another CNS active compound.

The invention furthermore provides methods of using compounds of this invention as positive controls in assays for receptor activity and using appropriately labeled compounds of
25 the invention as probes for the localization of receptors, particularly GABA_A receptors, in tissue sections.

30 DETAILED DESCRIPTION OF THE INVENTION

This invention relates to quinoline derivatives, pharmaceutical compositions comprising them, and the use of such compounds in the treatment of central nervous system and
35 peripheral diseases or disorders.

Accordingly, a broad embodiment of the invention is directed to compounds of Formula I:



Formula I

and the pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof, wherein:

R₁ is selected from:

hydrogen, halogen, hydroxy, C₁₋₆ alkyl, -O(C₁₋₆ alkyl), -NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₆ alkyl), -SO₂N(C₁₋₆ alkyl)(C₁₋₆ alkyl), amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)CO(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)CO₂(C₁₋₆ alkyl), -NHSO₂(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)SO₂(C₁₋₆ alkyl), -SO₂NHCO(C₁₋₆ alkyl), -CONHSO₂(C₁₋₆ alkyl), -CON(C₁₋₆ alkyl)(C₁₋₆ alkyl), -CO₂(C₁₋₆ alkyl), -S(C₁₋₆ alkyl), -SO(C₁₋₆ alkyl), or -SO₂(C₁₋₆ alkyl),

wherein said C₁₋₆ alkyl is straight, branched or cyclic, may contain one or two double or triple bonds, and is unsubstituted or substituted with one or more substituents selected from: hydroxy, oxo, fluoro, amino, C₁₋₃ alkoxy;

R₂ and R₃ are independently selected from the groups consisting of:

(1) C₁₋₈ alkyl, wherein said C₁₋₈ alkyl is straight, branched or cyclic, may contain one or two double or

triple bonds, and is unsubstituted or substituted with one or more of the substituents selected from:

(i) hydroxy,

(ii) oxo,

5 (iii) fluoro,

(iv) amino,

(v) Ar₁, wherein Ar₁ is independently selected at each occurrence from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzoimidazolyl, furanyl, 10 benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, triazolyl, tetrazolyl, pyrazolyl, and benzopyrazolyl, each of which is unsubstituted or substituted with one or more substituents selected from:

hydrogen, halogen, hydroxy, C₁₋₆ alkyl, -O(C₁₋₆ alkyl), -NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₆ alkyl), -SO₂N(C₁₋₆ alkyl)(C₁₋₆ alkyl), amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)CO(C₁₋₆ alkyl), 20 -N(C₁₋₆ alkyl)CO₂(C₁₋₆ alkyl), -NHSO₂(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)SO₂(C₁₋₆ alkyl), -SO₂NHCO(C₁₋₆ alkyl), -CONHSO₂(C₁₋₆ alkyl), -CON(C₁₋₆ alkyl)(C₁₋₆ alkyl), -CO₂(C₁₋₆ alkyl), -S(C₁₋₆ alkyl), -SO(C₁₋₆ alkyl), or -SO₂(C₁₋₆ alkyl), wherein C₁₋₆ alkyl, is defined as above,

(vi) -NR₅R₆, wherein R₅ and R₆ are independently selected at each occurrence from:

(a) hydrogen,

30 (b) C₁₋₆ alkyl, wherein C₁₋₆ alkyl is as defined above,

(c) -(CH₂)_n-Ar₁, wherein n is independently selected at each occurrence from 0, 1 or 2,

or the groups R₅ and R₆ are joined together to form a 4- to 8-membered ring may contain one or two double

bonds, or one or two oxo, or one or two O, S or N-R₇, wherein R₇ is independently selected at each occurrence from hydrogen, C₁₋₆ alkyl, -(CH₂)_n-Ar₁,

- 5 (vii) -OR₅, wherein R₅ is as defined above,
(viii) -CONR₅R₆ wherein R₅ and R₆ are as defined above,
(ix) -CO₂ R₅, wherein said R₅ is as defined above;

- 10 (2) Ar₂, wherein Ar₂ is independently selected at each occurrence from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzoimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl,
15 triazolyl, tetrazolyl, pyrazolyl, or benzopyrazolyl, and unsubstituted or substituted with one or more substituents selected from:

hydrogen, halogen, hydroxy, C₁₋₈ alkyl, -O(C₁₋₈ alkyl), -
20 NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₈ alkyl), -SO₂N(C₁₋₈ alkyl)(C₁₋₈ alkyl), amino, -NH(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO₂(C₁₋₈ alkyl), -NHSO₂(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)SO₂(C₁₋₈ alkyl), -SO₂NHCO(C₁₋₈ alkyl), -CONHSO₂(C₁₋₈ alkyl),
25 -CON(C₁₋₈ alkyl)(C₁₋₈ alkyl), -CO₂(C₁₋₈ alkyl), -S(C₁₋₈ alkyl), -SO(C₁₋₈ alkyl), or -SO₂(C₁₋₈ alkyl), wherein said C₁₋₈ alkyl is as defined above;

- (3) -NR₈R₉, wherein R₈ and R₉ are independently selected
30 at each occurrence from:

- (a) hydrogen,
(b) Ar₂,
(c) C₁₋₈ alkyl, wherein said C₁₋₈ alkyl is as defined
35 above;

or the groups R_8 and R_9 are joined together to form a 4- to 8-membered ring which ring of which the 4- to 8-membered ring may contain one or more double bonds, one
 5 or more oxo, one or more O, $S(O)_n$, $N-R_7$ wherein n and R_7 are as defined above; or one or more groups selected from the group consisting of hydroxy, halogen, amino, C_{1-8} alkyl, $-O(C_{1-8} \text{ alkyl})$, $-NO_2$, $-CN$, $-SO_2NH_2$, $-SO_2NH(C_{1-8} \text{ alkyl})$, $-SO_2N(C_{1-8} \text{ alkyl})(C_{1-8} \text{ alkyl})$,
 10 amino, $-NH(C_{1-8} \text{ alkyl})$, $-N(C_{1-8} \text{ alkyl})(C_{1-8} \text{ alkyl})$, $-N(C_{1-8} \text{ alkyl})CO(C_{1-8} \text{ alkyl})$, $-N(C_{1-8} \text{ alkyl})CO_2(C_{1-8} \text{ alkyl})$, $-NHSO_2(C_{1-8} \text{ alkyl})$, $-N(C_{1-8} \text{ alkyl})SO_2(C_{1-8} \text{ alkyl})$, $-SO_2NHCO(C_{1-8} \text{ alkyl})$, $-CONHSO_2(C_{1-8} \text{ alkyl})$, $-CON(C_{1-8} \text{ alkyl})(C_{1-8} \text{ alkyl})$, $-CO_2(C_{1-8} \text{ alkyl})$, $-S(C_{1-8} \text{ alkyl})$, $-SO(C_{1-8} \text{ alkyl})$, and $-SO_2(C_{1-8} \text{ alkyl})$,
 15 (4) $-OR_8$;

R_4 is selected from:

20 hydrogen, halogen, hydroxy, C_{1-8} alkyl, $-O(C_{1-8} \text{ alkyl})$, $-NO_2$, $-CN$, $-SO_2NH_2$, $-SO_2NH(C_{1-8} \text{ alkyl})$, $-SO_2N(C_{1-8} \text{ alkyl})(C_{1-8} \text{ alkyl})$, amino, $-NH(C_{1-8} \text{ alkyl})$, $-N(C_{1-8} \text{ alkyl})(C_{1-8} \text{ alkyl})$, $-N(C_{1-8} \text{ alkyl})CO(C_{1-8} \text{ alkyl})$, $-N(C_{1-8} \text{ alkyl})CO_2(C_{1-8} \text{ alkyl})$, $-NHSO_2(C_{1-8} \text{ alkyl})$, $-N(C_{1-8} \text{ alkyl})SO_2(C_{1-8} \text{ alkyl})$, $-SO_2NHCO(C_{1-8} \text{ alkyl})$, $-CONHSO_2(C_{1-8} \text{ alkyl})$, $-CON(C_{1-8} \text{ alkyl})(C_{1-8} \text{ alkyl})$, $-CO_2(C_{1-8} \text{ alkyl})$, $-S(C_{1-8} \text{ alkyl})$, $-SO(C_{1-8} \text{ alkyl})$, $-SO_2(C_{1-8} \text{ alkyl})$, and Ar_2 ;

X is $N-R_{10}$, wherein R_{10} is C_{1-8} alkyl;

30 Y_1 is $-CR_{11}R_{12}-$, $-CR_{11}R_{12}(CH_2)_p-$, or $(CH_2)_pCR_{11}R_{12}-$; where p is 0, 1, or 2;

Y_2 is $-CR_{11}R_{12}-$;


R_{11} and R_{12} are independently selected at each occurrence from:

35 (1) hydrogen, and

(2) C₁₋₈ alkyl; or

R₁₀ and R₁₁ are joined to form a 5- to 8-membered ring which may contain one or more double bonds; one O, S(O)_n, or N-R₇ wherein n and R₇ are as defined above; and which may be substituted with one or more of hydroxy, halogen, amino, C₁₋₈ alkyl, -O(C₁₋₈ alkyl), -NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₈ alkyl), -SO₂N(C₁₋₈ alkyl)(C₁₋₈ alkyl), amino, -NH(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO₂(C₁₋₈ alkyl), -NHSO₂(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)SO₂(C₁₋₈ alkyl), -SO₂NHCO(C₁₋₈ alkyl), -CONHSO₂(C₁₋₈ alkyl), -CON(C₁₋₈ alkyl)(C₁₋₈ alkyl), -CO₂(C₁₋₈ alkyl), -S(C₁₋₈ alkyl), or -SO(C₁₋₈ alkyl).

Preferred compounds of the invention include compounds of Formula IA




Formula IA

and the pharmaceutically acceptable salts and solvates thereof,

wherein: R₁, R₂, R₃, R₁₀, R₁₁ and R₁₂ are as defined for Formula I.

More preferred compounds of the invention include compounds of Formula IB



Formula IB

and the pharmaceutically acceptable salts and solvates
5 thereof,

wherein:

R₁ is hydrogen or fluorine; and

R₃, R₁₀, R₁₁ and R₁₂ are as defined for Formula I.

10 Particularly preferred compounds of Formula IB are those compounds wherein:


R₁₀ is C₁₋₈ alkyl; and

R₁₁ is hydrogen or C₁₋₈ alkyl.

15 Other preferred compounds of Formula IB are those compounds wherein:

R₁₀ and R₁₁ are joined to form a 5- to 8-membered ring which may contain one or more double bonds; one O, S(O)_n, or N-R₇, wherein n and R₇ are as defined above with regard to Formula I
20 in Claim 1; and which may be substituted with one or more of hydroxy, halogen, amino, C₁₋₈ alkyl, -O(C₁₋₈ alkyl), -NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₈ alkyl), -SO₂N(C₁₋₈ alkyl)(C₁₋₈ alkyl), amino, -NH(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO₂(C₁₋₈ alkyl), -NHSO₂(C₁₋₈ alkyl),
25 alkyl), -N(C₁₋₈ alkyl)SO₂(C₁₋₈ alkyl), -SO₂NHCO(C₁₋₈ alkyl), -CONHSO₂(C₁₋₈ alkyl), -CON(C₁₋₈ alkyl)(C₁₋₈ alkyl), -CO₂(C₁₋₈ alkyl), -S(C₁₋₈ alkyl), and -SO(C₁₋₈ alkyl).

Yet other preferred compounds of the invention are
30 compounds of Formula IC,



Formula IC

and the pharmaceutically acceptable salts and solvates thereof,

wherein


R_a , R_b , and R_c independently represent hydrogen, halogen, hydroxy, C_{1-6} alkyl, $-O(C_{1-6}$ alkyl), $-NO_2$, $-CN$, $-SO_2NH_2$, amino, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl)(C_{1-6} alkyl), $-N(C_{1-6}$ alkyl)CO(C_{1-6} alkyl), $-N(C_{1-6}$ alkyl)CO₂(C_{1-6} alkyl), $-CON(C_{1-6}$ alkyl)(C_{1-6} alkyl), $-CO_2(C_{1-6}$ alkyl), wherein C_{1-6} alkyl is as defined above;

R_1 is hydrogen or fluorine;

R_{10} is C_{1-8} alkyl; and

R_{11} and R_{12} are independently hydrogen or C_{1-8} alkyl.

Still other preferred compounds of the invention are compounds of Formula ID



Formula ID

and the pharmaceutically acceptable salts and solvates thereof,

wherein:

5 R_a , R_b , and R_c independently represent hydrogen, halogen, hydroxy, C_{1-6} alkyl, $-O(C_{1-6}$ alkyl), $-NO_2$, $-CN$, $-SO_2NH_2$, amino, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl)(C_{1-6} alkyl), $-N(C_{1-6}$ alkyl)CO(C_{1-6} alkyl), $-N(C_{1-6}$ alkyl)CO₂(C_{1-6} alkyl), $-CON(C_{1-6}$ alkyl)(C_{1-6} alkyl), $-CO_2(C_{1-6}$ alkyl), wherein C_{1-6} alkyl is as defined above;

10 R_1 is hydrogen or fluorine;

R_{12} is hydrogen or C_{1-8} alkyl; and

R_d and R_{10} together form an alkylene group of from 3-5 carbon atoms each of which is optionally substituted with methyl or ethyl.

15

In certain situations, the compounds of the present invention have asymmetric centers and this invention includes all of the optical isomers and mixtures thereof.

20 In addition, compounds with carbon-carbon double bonds may occur in Z- and E- forms with all isomeric forms of the compounds being included in the present invention.

25 When any variable (e.g. alkyl, Ar_1 , Ar_2 , R_5 , R_6 , R_8 , R_9 , R_{11} , R_{12} , etc.) occurs more than one time in Formula I, its definition on each occurrence is independent of its definition at every other occurrence.

30 As used herein, the term "alkyl" includes straight or branched chain alkyl groups and cycloalkyl groups that also may contain double or triple bonds. Examples of "alkyl" include methyl, ethyl, propyl, isopropyl, butyl, iso-, sec- and tert-butyl, pentyl, hexyl, heptyl, 3-ethylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 35 norbornyl, and the like. Where the number of carbon atoms is

designed the alkyl group includes that number of carbon atoms. When reference is made herein to C₁₋₆ alkyl which it may contain one or two double or triple bond it is understood that at least two carbons are present in the alkyl for one double
5 or triple bond, and at least four carbons for two double or triple bonds.

The term "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge, such as methoxy, ethoxy, propoxy and isopropoxy.

10 By the term "halogen" is meant fluorine, chlorine, bromine, and iodine.

The term "monocyclic" includes, but is not limited to cyclopentyl, cyclohexyl or cycloheptyl; "bicyclic" includes, but is not limited to indanyl, tetrahydronaphthyl, chromanyl
15 benzo[a][7]annulenyl, bicyclo[4.4.0]decanyl, bicyclo[4,3.0]nonanyl, bicyclo[3.3.0] octanyl; "tricyclic" includes, but is not limited to dibenzoannulenyl, dibenzoxepanyl, dibezothiepanyl.

20 As used herein, the terms "patients" refers to humans as well as other mammals including pets such as dogs and cats and livestock such as cattle and sheep.

This invention also includes methods for using compounds
25 of Formula I to treat diseases or disorders in patients in which mediation by GABA_A receptors is of importance.

Preferred compounds of this invention are ligands for GABA receptors, in particular the benzodiazepine site of GABA_A
30 receptors, and are useful in the treatment of a wide range of diseases or disorders of the central nervous system (CNS) and periphery in mammals in which modulation of GABA_A receptors is of importance. These include depression, anxiety, panic disorder, obsessive compulsive disorder, sleep disorders,
35 cognitive disorders, low alertness, neurodegenerative

disorders such as dementia, Alzheimer's diseases, Parkinson's disease, Huntington's disease, Down's syndrome, benzodiazepine overdoses, stress related somatic disorders. Compounds contained in the invention are also useful for the diagnosis
5 of disorders involving mediation by GABA_A receptors in patients.

Non-toxic pharmaceutical salts include salts, include, but not limited to salts with inorganic acids such as
10 hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrite or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, pamoate, salicylate and stearate.
15 Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium.

The present invention also encompasses the prodrugs of
20 the compounds of Formula I. Those skilled in the art will recognize various synthetic methodologies (references by N. Bodor, Drugs of the Future, 1981, 6, 165-182, or H. Bundgaard, Advanced Drug Delivery Reviews, 1989, 3, 39-65) which may be employed to prepare non-toxic pharmaceutically acceptable
25 prodrugs of the compounds encompassed by Formula I.

The compounds of general Formula I may be administered orally, topically, parenterally, by inhalation or spray or
30 rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition,
35 there is provided a pharmaceutical formulation comprising a

compound of general Formula I and a pharmaceutically acceptable carrier. One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or
5 adjuvants and if desired other active ingredients. The pharmaceutical compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft
10 capsules, or syrups or elixirs.

Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting
15 of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture
20 of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or
25 acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
30 For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate,
35 calcium phosphate or kaolin, or as soft gelatin capsules

wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting

agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring
5 agents, may also be present.

Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
10 Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation
15 products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or
20 sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those
25 suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among
30 the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-

or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of general Formula I may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

Compounds of general Formula I may be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.

Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most disorders, a dosage regimen of 4 times daily or less is preferred. For the treatment of anxiety or depression a dosage regimen of 1 or 2 times daily is particularly preferred. For the treatment of sleep disorders a single dose that rapidly reaches effective concentrations is desirable.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of

factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular
5 disease undergoing therapy.

Preferred compounds of the invention will have certain pharmacological properties. Such properties include, but are not limited to oral bioavailability, low toxicity, low serum protein binding and desirable *in vitro* and *in vivo* half-lives.
10 Penetration of the blood brain barrier for compounds used to treat CNS disorders is necessary, while low brain levels of compounds used to treat peripheral disorders are often preferred.

Assays may be used to predict these desirable
15 pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Toxicity to cultured hepatocytes may be used to predict compound toxicity. Penetration of the blood brain barrier of a
20 compound in humans may be predicted from the brain levels of the compound in laboratory animals given the compound intravenously.

Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by
25 Oravcová, et al. (Journal of Chromatography B (1996) volume 677, pages 1-27).

Compound half-life is inversely proportional to the frequency of dosage of a compound. *In vitro* half-lives of compounds may be predicted from assays of microsomal half-life
30 as described by Kuhnz and Gieschen (Drug Metabolism and Disposition, (1998) volume 26, pages 1120-1127).

The present invention also pertains to packaged pharmaceutical compositions for treating disorders responsive to GABA_A receptor modulation, e.g., treatment of cognitive
35 deficits, anxiety or depression by GABA_A receptor modulation.

The packaged pharmaceutical compositions include a container holding a therapeutically effective amount of at least one GABA_A receptor modulator as described supra and instructions (e.g., labeling) indicating the the contained GABA_A receptor
5 ligand is to be used for treating a disorder responsive to GABA_A receptor modulation in the patient.

The present invention also pertains to methods for altering the signal-transducing activity of GABA_A receptors, said method comprising exposing cells expressing such receptor
10 to an effective amount of a compound of the invention.

A method of inhibiting the binding of a benzodiazepine compound to the benzodiazepine site of the GABA_A receptor, comprising contacting a compound of Formula I with cells expressing such a receptor in the presence of a the
15 benzodiazepine compound, wherein the compound is present at a concentration sufficient to inhibit benzodiazepine compound binding to cells expressing a cloned human GABA_A receptor.

In a separate aspect, the invention provides a method of potentiating the actions of other CNS active compounds, which
20 comprises administering an effective amount of a compound of the invention in combination with another CNS active compound. Such CNS active compounds include, but are not limited to the following: for anxiety, serotonin receptor (e.g. 5-HT_{1A}) agonists and antagonists; for anxiety and depression,
25 neurokinin receptor antagonists or corticotropin releasing factor receptor (CRF₁) antagonists; for sleep disorders, melatonin receptor agonists; and for neurodegenerative disorders, such as Alzheimer's dementia, nicotinic agonists, muscarinic agents, acetylcholinesterase inhibitors and
30 dopamine receptor agonists. Particularly the invention provides a method of potentiating the antidepressant activity of selective serotonin reuptake inhibitors (SSRIs) by administering an effective amount of a GABA agonist compound of the invention in combination with an SSRI.

Combination administration can be carried out in an analogous fashion to that disclosed in Da-Rocha, et al., *J. Psychopharmacology* (1997) 11(3) 211-218; Smith, et al., *Am. J. Psychiatry* (1998) 155(10) 1339-45; and Le, et al., *Alcohol and Alcoholism* (1996) 31 Suppl. 127-132. Also see, the discussion of the use of the GABA_A receptor ligand 3-(5-methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl) methoxy-1,2,4-triazolo [3,4-a]phthalzine in combination with nicotinic agonists, muscarinic agonists, and acetylcholinesterase inhibitors, in PCT International publications Nos. WO 99/47142, WO 99/47171, and WO 99/47131, respectively. Also see in this regard PCT International publication No. WO 99/37303 for its discussion of the use of a class of GABA_A receptor ligands, 1,2,4-triazolo[4,3-b]pyridazines, in combination with SSRIs.

Preferred compounds of the invention show selectivity for the GABA_A receptor as compared to the NK-3 receptor as measured by standard assays for NK-3 and GABA_A Receptor binding (See example 13 for a standard assay of NK-3 receptor binding and example 14 for a standard assay of GABA_A receptor binding).


Preferred compounds exhibit a 10-fold greater affinity for the GABA_A receptor, more preferred compounds exhibit a 100-fold greater affinity for the GABA_A receptor, and most preferred compounds exhibit a 1000-fold greater affinity for the GABA_A receptor in a standard assay of GABA_A receptor binding than for the NK-3 receptor in a standard assay of Nk-3 receptor binding.

COMPOUND PREPARATION

Several methods for preparing the compounds of this invention are illustrated in the following Scheme I, II and III. The synthesis of compounds of Formula II is described in detail in the several publications including Giardina et. al. *J. Med. Chem.* **1997**, *40*, 1794-1807 and Giardina et. al. *J. Heterocyclic Chem.*, **1997**, *34*, 557-559 and references cited

therein. It will be recognized by those skilled in the art that the structures of Formula III, IV, and V can be readily synthesized from various readily available amino acids. Alternatively, various readily available ketones and aldehydes can be converted to the corresponding aminocyanides and cyanohydrins and subsequently reduced to the desired diamines and aminoalcohols. Those skilled in the art will recognize that in certain instances it will be necessary to utilize compounds of Formula II and Formula III bearing protecting groups and that these groups can be removed in a subsequent reaction to yield compounds of Formula I as described in "Protective Groups in Organic Synthesis", 2nd Ed., Greene, T. W. and related publications.

Scheme I




wherein R_1 , R_2 , R_3 , R_4 , R_{10} , R_{11} , and R_{12} are as defined above, W is $-CO_2H$, $-CO_2Me$, $-CO_2Et$, $-C(OEt)_3$, $-C=NHOMe$, $-C=NHOEt$, $-CSNH_2$, $-C=NHNH_2$, or $-CN$.

Condition A includes, but is not limited to, heating with or without a solvent such as toluene, ethanol, or xylene at 40-250 °C; heating with $AlMe_3$ in a solvent such as toluene at 80-120 °C and, occasionally, continued heating in the presence of Lawesson's reagent; or stirring at room temperature in

presence of triphenylphosphine, CCl_4 and a base such as triethylamine or diisopropylethylamine in a solvent such as acetonitrile or a mixture of solvents such as acetonitrile-pyridine.

5

Scheme II


10

wherein $R_1, R_2, R_3, R_4, R_{10}, R_{11}$, and R_{12} are as defined above, W is $-\text{COCl}$ or $-\text{CO}_2\text{H}$.

Condition B includes, but is not limited to, reaction of the amine with acid chloride ($W=\text{COCl}$) in the presence of base as well as amide bond forming conditions such as those employing the BOP reagent in the presence of base.

Condition C includes, but is not limited to, treatment with sodium methoxide in the presence of methanol as solvent.

20

Scheme III

wherein R_1 , R_2 , R_3 , R_4 , R_{11} , R_{12} are as defined above, W is $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{Me}$, $-\text{CO}_2\text{Et}$, $-\text{C}(\text{OEt})_3$, $-\text{C}=\text{NHOMe}$, $-\text{C}=\text{NHOEt}$, $-\text{CSNH}_2$, or $-\text{C}=\text{NHNH}_2$.


5 Condition A includes, but is not limited to, heating with or without a solvent such as toluene, ethanol, or xylene at 40-250 °C; heating with AlMe_3 in a solvent such as toluene at 80-120 °C and, occasionally, continued heating in the presence of Lawesson's reagent; or stirring at room temperature in
10 presence of triphenylphosphine, CCl_4 and a base such as triethylamine or diisopropylethylamine in a solvent such as acetonitrile or a mixture of solvents such as acetonitrile-pyridine.

15 Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention, as demonstrated by the following examples. In some cases protection of certain reactive functionalities may be
20 necessary to achieve some of the above transformations. In general the need for such protecting groups will be obvious to those skilled in the art of organic synthesis as well as the conditions necessary to attach and remove such groups.

25 The invention is illustrated further by the following examples which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them.

30

Example 1. S-3-(2-phenylquinolin-4-yl)-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole



A solution of trimethylaluminum in toluene (2.0 M, 1 mL) is added dropwise to a stirred solution of (S)-2-(aminomethyl)pyrrolidine (200mg, 2 mmol) in 5 mL of toluene at below 10°C under nitrogen. The resulting solution is heated at 60 °C for one hour and cooled to room temperature. 2-Phenyl-4-quinolinecarboxylate (263 mg, 1mmol) is added to the solution once. The reaction mixture is refluxed for 16 hours under nitrogen. After cooling, the solution is treated with 1 mL of water, diluted with 1mL of methanol and 1 mL of methylene chloride, and refluxed for 15 minutes. After separation of organic solvent and solvent evaporation, the residue is purified over silica gel chromatography eluting with 5-10% MeOH/CH₂Cl₂ to give 76 mg of the titled compound. ¹H NMR (CDCl₃) δ 1.5-2.1 (m, 3 H), 2.95-3.20 (m, 2 H), 3.98-4.30 (m, 3 H), 2.13 (m, 2 H), 7.40-7.60 (m, 4 H), 7.75 (t, 1 H), 8.15 (s, 1 H), 8.22 (m, 3 H), 8.53 (d, 1 H). MS (ES⁺): 314 [MH]⁺.

Examples 2 - 12

Accordingly, the following compounds are prepared by analogous procedure described for example 1.

Example 2. S-3-[2-(6-Fluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole.

Example 3. S-3-[2-(2-Fluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole.

Example 4. S-3-[2-(4-Fluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole.

Example 5. S-3-[2-(2,3-Difluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole

Example 6. S-3-[2-(2,4-Difluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole.

Example 7. S-3-[2-(3-thienyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole.

5 Example 8. 1-Methyl-2-(2-phenylquinolin-4-yl)-4,5-dihydro-1H-Imidazole.

Example 9. 1-Ethyl-2-(2-phenylquinolin-4-yl)-4,5-dihydro-1H-Imidazole.

10 Example 10. 1,5-Dimethyl-2-(2-phenylquinolin-4-yl)-4,5-dihydro-1H-Imidazole.

Example 11. 1-Methyl-2--(2-phenylquinolin-4-yl)-1,4,5,6-tetrahydro-Pyrimidine.

Example 12. 1-Ethyl-2--(2-phenylquinolin-4-yl)-1,4,5,6-tetrahydro-Pyrimidine.

15

Example 13

Assay For NK-3 Receptor Binding Activity

The following assay is a standard assay for NK-3 receptor binding activity. Assays are performed as described in Krause et al (Proc. Natl. Acad. Sci. USA 94: 310-315, 1997). The NK-3 receptor complementary DNA was cloned from human hypothalamic RNA using standard procedures. The receptor cDNA was inserted into the expression vector pM² to transfect the mammalian Chinese hamster ovary cell line, and a stably expressing clonal cell line was isolated, characterized and used for the current experiments. Cells are grown in minimal essential medium alpha containing 10% fetal bovine serum and 250 µg/ml G418. Cells were liberated from cell culture plates with No-zyne (PBS base, JRH Biosciences), and harvested by low speed centrifugation. The cell pellet was homogenized in TBS (0.05 M TrisHCl, 120 mM NaCl, pH 7.4) with a Polytron homogenizer at setting 5 for 20 seconds, and total cellular membranes were isolated by centrifugation at 47,500 x g for 10 minutes. The membrane pellet was resuspended by

homogenization with the Polytron as above, and the membranes were isolated by centrifugation at 47,500 x g for 10 minutes. This final membrane pellet was resuspended in TBS at a protein concentration of 350 µg/ml.

5

Receptor binding assays contain a total volume of 200 µl containing 50 µg membrane protein, 0.05-0.15 nM 125I-methylPhe7-neurokinin B, drug or blocker in TBS containing 1.0 mg/ml bovine serum albumen, 0.2 mg/ml bacitracin, 20 µg/ml
10 leupeptin and 20 µg/ml chymostatin. Incubations are carried out for 2 hours at 4 °C, and the membrane proteins are harvested by passing the incubation mixture by rapid filtration over presoaked GF/B filters to separate bound from free ligand. The filters are presoaked in TBS containing 2%
15 BSA and 0.1% Tween 20. After filtration of the incubation mixture, filters are rinsed 4 times with ice-cold TBS containing 0.01% sodium dodecyl sulfate and radioactivity is quantitated in a β-plate scintillation counter. One µM methylPhe7-neurokinin B is added to some tubes to determine
20 nonspecific binding. Data are collected in duplicate determinations, averaged, and the percent inhibition of total specific binding is calculated. The total specific binding is the total binding minus the nonspecific binding. In many cases, the concentration of unlabeled drug is varied and total
25 displacement curves of binding is carried out. Data are converted to a form for the calculation of IC₅₀ and Hill coefficient (nH).

Example 14

30

Assay for GABA_A Receptor Binding

The following assay is a standard assay for GABA_A receptor binding.

The high affinity and high selectivity of compounds of this invention for the benzodiazepine site of the GABA_A receptor is confirmed using the binding assay described in Thomas and Tallman (*J. Bio. Chem.* 1981; 156:9838-9842, and *J. Neurosci.* 1983; 3:433-440).

Rat cortical tissue is dissected and homogenized in 25 volumes (w/v) of Buffer A (0.05 M Tris HCl buffer, pH 7.4 at 4 °C). The tissue homogenate is centrifuged in the cold (4 °C) at 20,000 x g for 20 minutes. The supernatant is decanted, the pellet rehomogenized in the same volume of buffer, and centrifuged again at 20,000 x g. The supernatant of this centrifugation step is decanted and the pellet stored at -20 °C overnight. The pellet is then thawed and resuspended in 25 volumes of Buffer A (original wt/vol), centrifuged at 20,000 x g and the supernatant decanted. This wash step is repeated once. The pellet is finally resuspended in 50 volumes of Buffer A.

Incubations containing 100 µl of tissue homogenate, 100 µl of radioligand, (0.5 nM ³H-Ro15-1788 [³H-Flumazenil], specific activity 80 Ci/mmol), and test compound or control (see below), and are brought to a total volume of 500 µl with Buffer A. Incubations are carried for 30 min at 4°C and then rapidly filtered through Whatman GFB filters to separate free and bound ligand. Filters are washed twice with fresh Buffer A and counted in a liquid scintillation counter. Nonspecific binding (control) is determined by displacement of ³H Ro15-1788 with 10 µM Diazepam (Research Biochemicals International, Natick, MA). Data were collected in triplicate, averaged, and percent inhibition of total specific binding (Total Specific Binding = Total - Nonspecific) was calculated for each compound.

A competition binding curve is obtained with up to 11 points spanning the compound concentration range from 10⁻¹²M to 10⁻⁵M obtained per curve by the method described above for determining percent inhibition. K_i values are calculated

according the Cheng-Prussof equation. When tested in this assay compounds of the invention exhibit K_i values of less than 1 μ M, preferred compounds of the invention have K_i values of less than 500 nM and more compounds of the invention have K_i values of less than 100 nM.

Example 15

Assay for GABA_A Receptor Functional Activity

10 Electrophysiology

The following assay is used to determine if a compound of the invention act as an agonist, an antagonist, or an inverse agonist at the benzodiazepine site of the GABA_A receptor.

Assays are carried out as described in White and Gurley
15 (NeuroReport 6: 1313-1316, 1995) and White, Gurley, Hartnett, Stirling, and Gregory (Receptors and Channels 3: 1-5, 1995) with modifications. Electrophysiological recordings are carried out using the two electrode voltage-clamp technique at a membrane holding potential of -70 mV. *Xenopus Laevis* oocytes
20 are enzymatically isolated and injected with non-polyadenylated cRNA mixed in a ratio of 4:1:4 for α , β and γ subunits, respectively. Of the nine combinations of α , β and γ subunits described in the White et al. publications, preferred combinations are $\alpha_1\beta_2\gamma_2$, $\alpha_2\beta_3\gamma_2$, $\alpha_3\beta_3\gamma_2$, and $\alpha_5\beta_3\gamma_2$. Preferably all
25 of the subunit cRNAs in each combination are human clones or all are rat clones. The sequence of each of these cloned subunits is available from GENBANK, e.g., human α_1 , GENBANK accession no. X14766, human α_2 , GENBANK accession no. A28100; human α_3 , GENBANK accession no. A28102; human α_5 , GENBANK
30 accession no. A28104; human β_2 , GENBANK accession no. M82919; human β_3 , GENBANK accession no. Z20136; human γ_2 , GENBANK accession no. X15376; rat α_1 , GENBANK accession no. L08490, rat α_2 , GENBANK accession no. L08491; rat α_3 , GENBANK accession

no. L08492; rat α_5 , GENBANK accession no. L08494; rat β_2 , GENBANK accession no. X15467; rat β_3 , GENBANK accession no. X15468; and rat β_2 , GENBANK accession no. L08497. For each subunit combination, sufficient message for each constituent subunit is injected to provide current amplitudes of >10 nA when 1 μ M GABA is applied.

Compounds are evaluated against a GABA concentration that evokes <10% of the maximal evokable GABA current (e.g. 1 μ M - 9 μ M). Each oocyte is exposed to increasing concentrations of compound in order to evaluate a concentration/effect relationship. Compound efficacy is calculated as a percent-change in current amplitude: $100*((I_c/I)-1)$, where I_c is the GABA evoked current amplitude observed in the presence of test compound and I is the GABA evoked current amplitude observed in the absence of the test compound.

Specificity of a compound for the benzodiazepine site is determined following completion of a concentration/effect curve. After washing the oocyte sufficiently to remove previously applied compound, the oocyte is exposed to GABA + 1 μ M RO15-1788, followed by exposure to GABA + 1 μ M RO15-1788 + test compound. Percent change due to addition of compound is calculated as described above. Any percent change observed in the presence of RO15-1788 is subtracted from the percent changes in current amplitude observed in the absence of 1 μ M RO15-1788. These net values are used for the calculation of average efficacy and EC_{50} values by standard methods. To evaluate average efficacy and EC_{50} values, the concentration/effect data are averaged across cells and fit to the logistic equation.

30

Example 16

Preparation of radiolabeled probe compounds of the invention

The compounds of the invention are prepared as radiolabeled probes by carrying out their synthesis using precursors comprising at least one atom that is a radioisotope. The radioisotope is preferably selected from of
5 at least one of carbon (preferably ^{14}C), hydrogen (preferably ^3H), sulfur (preferably ^{35}S), or iodine (preferably ^{125}I). Such radiolabeled probes are conveniently synthesized by a radioisotope supplier specializing in custom synthesis of radiolabeled probe compounds. Such suppliers include Amersham
10 Corporation, Arlington Heights, IL; Cambridge Isotope Laboratories, Inc. Andover, MA; SRI International, Menlo Park, CA; Wizard Laboratories, West Sacramento, CA; ChemSyn Laboratories, Lexena, KS; American Radiolabeled Chemicals, Inc., St. Louis, MO; and Moravek Biochemicals Inc., Brea, CA.

15 Tritium labeled probe compounds are also conveniently prepared catalytically via platinum-catalyzed exchange in tritiated acetic acid, acid-catalyzed exchange in tritiated trifluoroacetic acid, or heterogeneous-catalyzed exchange with tritium gas. Such preparations are also conveniently carried
20 out as a custom radiolabeling by any of the suppliers listed in the preceding paragraph using the compound of the invention as substrate. In addition, certain precursors may be subjected to tritium-halogen exchange with tritium gas, tritium gas reduction of unsaturated bonds, or reduction using
25 sodium borotritide, as appropriate.

Example 17

Use of compounds of the invention as probes for GABA_A receptors in cultured cells and tissue samples


30 Receptor autoradiography (receptor mapping) of GABA_A receptors in cultured cells or tissue samples is carried out in vitro as described by Kuhar in sections 8.1.1 to 8.1.9 of Current Protocols in Pharmacology (1998) John Wiley & Sons,

New York, using radiolabeled compounds of the invention prepared as described in the preceding Example.

5 The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the
10 present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

WHAT IS CLAIMED IS:

1. A compound of the formula:



5 or pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, wherein:

R₁ is selected from:

hydrogen, halogen, hydroxy, C₁₋₆ alkyl, -O(C₁₋₆ alkyl), -
 10 NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₆ alkyl), -SO₂N(C₁₋₆ alkyl)(C₁₋₆
 alkyl), amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)(C₁₋₆ alkyl),
 -N(C₁₋₆ alkyl)CO(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)CO₂(C₁₋₆ alkyl) ,
 -NHSO₂(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)SO₂(C₁₋₆ alkyl), -
 15 SO₂NHCO(C₁₋₆ alkyl), -CONHSO₂(C₁₋₆ alkyl), -CON(C₁₋₆ alkyl)
 (C₁₋₆ alkyl), -CO₂(C₁₋₆ alkyl), -S(C₁₋₆ alkyl), -SO(C₁₋₆
 alkyl), or -SO₂(C₁₋₆ alkyl),

wherein said C₁₋₆ alkyl is straight, branched or cyclic,
 may contain one or two double or triple bonds, and is
 20 unsubstituted or substituted with one or more
 substituents selected from: hydroxy, oxo, fluoro, amino,
 C₁₋₃ alkoxy;

R₂ and R₃ are independently selected from the groups
 25 consisting of:

(1) C₁₋₈ alkyl, wherein said C₁₋₈ alkyl is straight,
 branched or cyclic, may contain one or two double or
 triple bonds, and is unsubstituted or substituted with
 30 one or more of the substituents selected from:

(i) hydroxy,

(ii) oxo,

(iii) fluoro,

(iv) amino,

(v) Ar₁, wherein Ar₁ is independently selected at each occurrence from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzoimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, triazolyl, tetrazolyl, pyrazolyl, and benzopyrazolyl, each of which is unsubstituted or substituted with one or more substituents selected from:

hydrogen, halogen, hydroxy, C₁₋₆ alkyl, -O(C₁₋₆ alkyl), -NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₆ alkyl), -SO₂N(C₁₋₆ alkyl)(C₁₋₆ alkyl), amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)CO(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)CO₂(C₁₋₆ alkyl), -NHSO₂(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)SO₂(C₁₋₆ alkyl), -SO₂NHCO(C₁₋₆ alkyl), -CONHSO₂(C₁₋₆ alkyl), -CON(C₁₋₆ alkyl)(C₁₋₆ alkyl), -CO₂(C₁₋₆ alkyl), -S(C₁₋₆ alkyl), -SO(C₁₋₆ alkyl), or -SO₂(C₁₋₆ alkyl), wherein C₁₋₆ alkyl, is defined as above,

(vi) -NR₅R₆, wherein R₅ and R₆ are independently selected at each occurrence from:

(a) hydrogen,

(b) C₁₋₆ alkyl, wherein C₁₋₆ alkyl is as defined above,

(c) -(CH₂)_n-Ar₁, wherein n is independently selected at each occurrence from 0, 1 or 2,

or the groups R₅ and R₆ are joined together to form a 4- to 8-membered ring which may contain one or two double bonds, or one or two oxo, or one or two O, S or N-R₇ wherein R₇ is independently selected at each occurrence from hydrogen, C₁₋₆ alkyl, -(CH₂)_n-Ar₁,

- (vii) $-OR_5$, wherein R_5 is as defined above,
(viii) $-CONR_5R_6$ wherein R_5 and R_6 are as defined
above,
5 (ix) $-CO_2 R_5$, wherein said R_5 is as defined above;

(2) Ar_2 , wherein Ar_2 is independently selected at each
occurrence from phenyl, naphthyl, thienyl, benzothienyl,
pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl,
10 benzoimidazolyl, furanyl, benzofuranyl, thiazolyl,
benzothiazolyl, isothiazolyl, benzisothiazolyl,
triazolyl, tetrazolyl, pyrazolyl, or benzopyrazolyl, and
is unsubstituted and substituted with one or more
substituents selected from:

15 hydrogen, halogen, hydroxy, C_{1-8} alkyl, $-O(C_{1-8}$ alkyl), $-$
 NO_2 , $-CN$, $-SO_2NH_2$, $-SO_2NH(C_{1-8}$ alkyl), $-SO_2N(C_{1-8}$
alkyl)(C_{1-8} alkyl), amino, $-NH(C_{1-8}$ alkyl), $-N(C_{1-8}$
alkyl)(C_{1-8} alkyl), $-N(C_{1-8}$ alkyl)CO(C_{1-8} alkyl), $-$
20 $N(C_{1-8}$ alkyl)CO $_2$ (C_{1-8} alkyl), $-NHSO_2(C_{1-8}$ alkyl), $-N(C_{1-8}$
alkyl)SO $_2$ (C_{1-8} alkyl), $-SO_2NHCO(C_{1-8}$ alkyl), $-CONHSO_2(C_{1-8}$
alkyl), $-CON(C_{1-8}$ alkyl)(C_{1-8} alkyl), $-CO_2(C_{1-8}$ alkyl), $-$
 $S(C_{1-8}$ alkyl), $-SO(C_{1-8}$ alkyl), or $-SO_2(C_{1-8}$ alkyl),
wherein said C_{1-8} alkyl is as defined above;

25 (3) $-NR_8R_9$, wherein R_8 and R_9 are independently selected
at each occurrence from:

- (a) hydrogen,
30 (b) Ar_2 ,
(c) C_{1-8} alkyl, wherein said C_{1-8} alkyl is as defined
above;

or the groups R_8 and R_9 are joined together to form a
35 which ring may contain one or more double bonds; one or

more oxo; one or more O, S(O)_n, N-R₇ wherein n and R₇ are as defined above; or one or more of hydroxy, halogen, amino, C₁₋₈ alkyl, -O(C₁₋₈ alkyl), -NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₈ alkyl), -SO₂N(C₁₋₈ alkyl) (C₁₋₈ alkyl), amino, -NH(C₁₋₈ alkyl), -N(C₁₋₈ alkyl) (C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO₂(C₁₋₈ alkyl), -NHSO₂(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)SO₂(C₁₋₈ alkyl), -SO₂NHCO(C₁₋₈ alkyl), -CONHSO₂(C₁₋₈ alkyl), -CON(C₁₋₈ alkyl) (C₁₋₈ alkyl), -CO₂(C₁₋₈ alkyl), -S(C₁₋₈ alkyl), -SO(C₁₋₈ alkyl), or -SO₂(C₁₋₈ alkyl),
 (4) -OR₈;

R₄ is selected from:

hydrogen, halogen, hydroxy, C₁₋₈ alkyl, -O(C₁₋₈ alkyl), -NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₈ alkyl), -SO₂N(C₁₋₈ alkyl) (C₁₋₈ alkyl), amino, -NH(C₁₋₈ alkyl), -N(C₁₋₈ alkyl) (C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO₂(C₁₋₈ alkyl), -NHSO₂(C₁₋₈ alkyl), -N(C₁₋₆ alkyl)SO₂(C₁₋₈ alkyl), -SO₂NHCO(C₁₋₈ alkyl), -CONHSO₂(C₁₋₈ alkyl), -CON(C₁₋₈ alkyl) (C₁₋₈ alkyl), -CO₂(C₁₋₈ alkyl), -S(C₁₋₈ alkyl), -SO(C₁₋₈ alkyl), -SO₂(C₁₋₈ alkyl), and Ar₂;

X is N-R₁₀, wherein R₁₀ is C₁₋₈ alkyl;

Y₁ is -CR₁₁R₁₂-, -CR₁₁R₁₂(CH₂)_p-, or (CH₂)_pCR₁₁R₁₂-; where p is 0, 1, or 2;

Y₂ is -CR₁₁R₁₂-;


R₁₁ and R₁₂ are independently selected at each occurrence from:

(1) hydrogen, and
 (2) C₁₋₈ alkyl; or

R₁₀ and R₁₁ may be joined to form a 5- to 8-membered ring which may contain one or more double bonds; one O, S(O)_n, or N-R₇ wherein n and R₇ are as defined above; and which may be substituted with one or more of hydroxy, halogen,


amino, C₁₋₈ alkyl, -O(C₁₋₈ alkyl), -NO₂, -CN, -SO₂NH₂, -
 SO₂NH(C₁₋₈ alkyl), -SO₂N(C₁₋₈ alkyl)(C₁₋₈ alkyl), amino,
 -NH(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -N(C₁₋₈
 alkyl)CO(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO₂(C₁₋₈ alkyl), -
 5 NHSO₂(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)SO₂(C₁₋₈ alkyl), -SO₂NHCO(C₁₋₈
 alkyl), -CONHSO₂(C₁₋₈ alkyl), -CON(C₁₋₈ alkyl)(C₁₋₈ alkyl),
 -CO₂(C₁₋₈ alkyl), -S(C₁₋₈ alkyl), and -SO(C₁₋₈ alkyl).

10 2. A compound according to Claim 1, of the formula



or a pharmaceutically acceptable salt or solvate thereof,
 wherein: R₁, R₂, R₃, R₁₀, R₁₁ and R₁₂ are as defined in Claim 1.

15 3. A compound according to Claim 1, of the formula




or a pharmaceutically acceptable salt or solvate thereof,
 wherein:

R₁ is hydrogen or fluorine; and

20 R₃, R₁₀, R₁₁ and R₁₂ are as defined in Claim 1.

4. A compound according to claim 1, or the formula:



wherein:


R₁ is hydrogen or fluorine;

R₃ and R₁₂ are as defined in Claim 1;

5 R₁₀ is C₁₋₈ alkyl; and

R₁₁ is hydrogen or C₁₋₈ alkyl.

5. A compound according to claim 1, or the formula:



10

wherein:


R₁ is hydrogen or fluorine;

R₃ and R₁₂ are as defined in Claim 1;

15 R₁₀ and R₁₁ are joined to form a 5- to 8-membered ring which may contain one or more double bonds; one O, S(O)_n, or N-R₇ wherein n and R₇ are as defined in Claim 1; and which may be substituted with one or more of hydroxy, halogen, amino, C₁₋₈ alkyl, -O(C₁₋₈ alkyl), -NO₂, -CN, -SO₂NH₂, -SO₂NH(C₁₋₅ alkyl), -SO₂N(C₁₋₈ alkyl)(C₁₋₈ alkyl), amino, -NH(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)CO₂(C₁₋₈ alkyl), -NHSO₂(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)SO₂(C₁₋₈ alkyl), -SO₂NHCO(C₁₋₈ alkyl), -CONHSO₂(C₁₋₈ alkyl), -CON(C₁₋₈ alkyl)(C₁₋₈ alkyl), -CO₂(C₁₋₈ alkyl), -S(C₁₋₈ alkyl), or -SO(C₁₋₈ alkyl).

25

6. A compound according to Claim 1, of the formula



or a pharmaceutically acceptable salt or solvate thereof,

5 where

R_a , R_b , and R_c independently represent hydrogen, halogen, hydroxy, C_{1-6} alkyl, $-O(C_{1-6}$ alkyl), $-NO_2$, $-CN$, $-SO_2NH_2$, amino, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl)(C_{1-6} alkyl), $-N(C_{1-6}$ alkyl)CO(C_{1-6} alkyl), $-N(C_{1-6}$ alkyl)CO₂(C_{1-6} alkyl), $-CON(C_{1-6}$ alkyl)(C_{1-6} alkyl), or $-CO_2(C_{1-6}$ alkyl), wherein C_{1-6} alkyl is as defined above;


R_1 is hydrogen or fluorine;

R_{10} is C_{1-8} alkyl; and

R_{11} and R_{12} are independently hydrogen or C_{1-8} alkyl.

15

7. A compound according to Claim 1, of the formula



or a pharmaceutically acceptable salt or solvate thereof,

where

20 R_a , R_b , and R_c independently represent hydrogen, halogen, hydroxy, C_{1-6} alkyl, $-O(C_{1-6}$ alkyl), $-NO_2$, $-CN$, $-SO_2NH_2$,

amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)CO(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)CO₂(C₁₋₆ alkyl), -CON(C₁₋₆ alkyl)(C₁₋₆ alkyl), or -CO₂(C₁₋₆ alkyl), wherein C₁₋₆alkyl is as defined above;

5 R₁ is hydrogen or fluorine;

R₁₂ is hydrogen or C₁₋₈ alkyl; and

R_d and R₁₀ together form an alkylene group of from 3-5 carbon atoms each of which is optionally substituted with methyl or ethyl.

10

8. A compound according to claim 1, which is :
S-3-(2-phenylquinolin-4-yl)-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole.

15 9. A compound according to claim 1, which is selected from:

S-3-[2-(6-Fluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole;

20 S-3-[2-(2-Fluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole;

S-3-[2-(4-Fluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole;

S-3-[2-(2,3-Difluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole;

25 S-3-[2-(2,4-Difluorophenyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole;

S-3-[2-(3-thienyl)quinolin-4-yl]-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole;

1-Methyl-2-(2-phenylquinolin-4-yl)-4,5-dihydro-1H-Imidazole;

30 1-Ethyl-2-(2-phenylquinolin-4-yl)-4,5-dihydro-1H-Imidazole;

1,5-Dimethyl-2-(2-phenylquinolin-4-yl)-4,5-dihydro-1H-Imidazole;

1-Methyl-2--(2-phenylquinolin-4-yl)-1,4,5,6-tetrahydro-Pyrimidine; and

1-Ethyl-2--(2-phenylquinolin-4-yl)-1,4,5,6-tetrahydro-
Pyrimidine.

10. A compound as claimed in any preceding claim for use
5 in therapeutic treatment of a disease or disorder associated
with pathogenic agonism, inverse agonism or antagonism of the
GABA_A receptor.

11. A pharmaceutical composition comprising a compound
10 according to Claim 1 combined with at least one
pharmaceutically acceptable carrier or excipient.

12. A method for the treatment or prevention of a
disease or disorder associated with pathogenic associated with
15 pathogenic agonism, inverse agonism or antagonism of the GABA_A
receptor, said method comprising administering to a patient in
need of such treatment or prevention an effective amount of a
compound of claim 1.

20

13. The use of a compound according to Claim 1 for the
manufacture of a medicament for the treatment or prevention of
a disease or disorder associated with pathogenic agonism,
inverse agonism or antagonism of the GABA_A receptor.

25

14. The use of a compound according to Claim 1 for the
manufacture of a medicament for the treatment or prevention of
anxiety, depression, sleep disorders, or cognitive impairment.

30

15. A method according to Claim 12 wherein the disease or
disorder associated with pathogenic agonism, inverse agonism
or antagonism of the GABA_A receptor is anxiety, depression, a
sleep disorder, or cognitive impairment.

35

16. A method for localizing GABA_A receptors in a tissue
sample comprising:

contacting with the sample a detectably-labeled compound of claim 1 under conditions that permit binding of the compound to GABA_A receptors, washing the sample to remove unbound compound, and detecting the bound compound.

5

17. A method for altering the signal-transducing activity of GABA_A receptors, said method comprising exposing cells expressing such receptors to a compound according to claim 1 at a concentration sufficient to inhibit RO15-1788 binding to
10 cells expressing a cloned human GABA_A receptor *in vitro*.

18. A packaged pharmaceutical composition comprising the pharmaceutical composition of Claim 11 in a container and instructions for using the composition to treat a patient
15 suffering from a disorder responsive to agonism, inverse agonism or antagonism of the GABA_A receptor.

19. The packaged pharmaceutical composition of claim 18, wherein said patient is suffering from anxiety, depression, a
20 sleep disorder, or cognitive impairment.

20. A compound according to claim 1 wherein in a standard assay of GABA_A receptor binding the compound exhibits an IC₅₀ of 1 micromolar or less.

25

21. A compound according to claim 1 wherein in a standard assay of GABA_A receptor binding the compound exhibits an IC₅₀ of 100 nanomolar or less.

30 22. A compound according to claim 1 wherein in a standard assay of GABA_A receptor binding the compound exhibits an IC₅₀ of 10 nanomolar or less.

23. A compound according to claim 1 wherein the compound
35 exhibits a 100-fold greater affinity for the GABA_A receptor in

a standard assay of GABA_A receptor binding than for the NK-3 receptor in a standard assay of NK-3 receptor binding.

24. A compound according to claim 1 wherein the compound
5 exhibits a 1000-fold greater affinity for the GABA_A receptor
in a standard assay of GABA_A receptor binding than for the NK-
3 receptor in a standard assay of NK-3 receptor binding.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/08196

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/47 A61P43/00 C07D401/04
//(C07D487/04,235:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PIERO SAVARINO ET AL.: "Assembled systems (X-azolopyridine)(quinoline). Bases and Salts." JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 29, - 1992 pages 185-192, XP002144891 HETEROCORPORATION. PROVO., US ISSN: 0022-152X * compound 16 *	1
A	WO 95 11885 A (NEUROGEN CORPORATION) 4 May 1995 (1995-05-04) page 12 -page 15	1,11,13
A	US 5 792 766 A (PAUL CHEN ET AL.) 11 August 1998 (1998-08-11) column 11, line 46 - line 52; claim 1 -/-	1,11,13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 August 2000

Date of mailing of the international search report

06/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/08196

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 96 02509 A (SMITHKLINE BEECHAM FARMACEUTICI S.P.A.) 1 February 1996 (1996-02-01) page 1, line 21 - line 35; claim 1 -----</p>	1, 11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/08196

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9511885 A	04-05-1995	US 5484944 A	16-01-1996
		AT 168673 T	15-08-1998
		AU 701151 B	21-01-1999
		AU 8126594 A	22-05-1995
		CA 2175204 A	11-05-1995
		CN 1143953 A	26-02-1997
		CZ 9601129 A	16-04-1997
		DE 69411939 D	27-08-1998
		DE 69411939 T	25-03-1999
		EP 0725775 A	14-08-1996
		EP 0825193 A	25-02-1998
		ES 2122504 T	16-12-1998
		FI 961776 A	14-06-1996
		HU 76064 A	30-06-1997
		JP 9506082 T	17-06-1997
		KR 181383 B	20-03-1999
		NO 961655 A	10-06-1996
		NZ 275968 A	27-05-1998
		PL 314136 A	19-08-1996
		RU 2125989 C	10-02-1999
		SE 9601563 A	22-05-1996
		SE 9902648 A	09-07-1999
		SK 52496 A	09-07-1997
		US 5925770 A	20-07-1999
		US 5608079 A	04-03-1997
		US 5750702 A	12-05-1998
US 5792766 A	11-08-1998	AU 2321597 A	01-10-1997
		EP 0896578 A	17-02-1999
		WO 9733889 A	18-09-1997
WO 960250 A	01-02-1996	IT 1270615 B	07-05-1997